Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review Article

COVID-19-related myocarditis and cholinergic anti-inflammatory pathways

Weike Liu 1, Zhendong Liu 2,*, Yue-Chun Li 1,**

1 Department of Cardiology, Second Affiliated Hospital and Yang’s Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China
2 Basic Medicine College, Shandong First Medical University, Jinan, Shandong, 250062, China

A R T I C L E   I N F O

Article history:
Received 29 September 2020
Received in revised form
19 November 2020
Accepted 3 December 2020
Available online 8 December 2020

Keywords:
Severe acute respiratory syndrome coronavirus-2
Myocarditis
Cholinergic anti-inflammatory pathway

A B S T R A C T

Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2, is currently in a pandemic outbreak and has become a global health issue. In addition to the primarily involvement of the respiratory system, myocarditis is considered an important and fatal lesion in patients with COVID-19. However, effective therapeutic methods are currently lacking. The cholinergic anti-inflammatory pathway (CAP) has been demonstrated to suppress pro-inflammatory cytokine production and control inflammation in sepsis and other medical conditions. Therefore, the CAP may be a potential and effective therapeutic method for COVID-19-related myocarditis. This article reviews the relationship between COVID-19-related myocarditis and the CAP and discusses the CAP as a potential therapeutic modality in the treatment of COVID-19-related myocarditis.

© 2020 Hellenic Society of Cardiology. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The coronavirus disease-2019 (COVID-19), whose current outbreak has resulted in a pandemic with significant mortality,1-5 is caused by a novel single-stranded RNA virus between 26 and 32 kb in length; this virus is the seventh known corona virus to infect humans and was named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the WHO.6,7 Similar to the Severe Acute Respiratory Syndrome (SARS) outbreak in 2002 and Middle East Respiratory Syndrome (MERS) outbreak in 2012,7,10 COVID-19 quickly spread worldwide and has affected human health and the economy on an unprecedented scale since its initial outbreak in December 2019.2-4,11 Although the case fatality rate is less than that of SARS (9.6%) and MERS (34.4%), COVID-19 has claimed more lives than SARS and MERS combined.3,7,12

The primary organs involved in COVID-19 are those in the respiratory system, which is affected by the acute respiratory distress syndrome (ARDS).6,11 However, multiorgan damage/failure develops in most cases.6,13-17 The myocardium and immune system appear to be particularly susceptible to SARS-CoV-2.6,14-19 Myocarditis, a specific cardiovascular manifestation with fatal outcomes, has been reported to be a potential etiology underlying myocardial injury in patients with COVID-19.12,20-24 A retrospective multicenter study has attributed 40% (29 patients) of cases to myocarditis with circulatory failure or respiratory failure among 68 fatal cases of COVID-19.25 A “cytokine storm” triggered by immunological dysregulation is considered to underlie COVID-19-related myocarditis,5,26 although the mechanisms of myocardial inflammation in COVID-19 remain unclear.27,28

The cholinergic anti-inflammatory pathway (CAP), a neuroimmunomodulatory pathway, suppresses pro-inflammatory cytokine production and controls inflammation in sepsis and other medical conditions.29-34 For therapeutic purposes, CAP activation can ameliorate lung injury,35 rheumatoid arthritis,35,36 acute kidney injury,37 and Alzheimer’s disease.38 Recently, the CAP has been recommended for patients with COVID-19.24,42

In this article, we briefly review COVID-19-related myocarditis and the CAP, and we discuss the CAP as a therapeutic modality in the treatment of COVID-19-related myocarditis.
2. Incidence of COVID-19-related myocarditis

Biopsy studies have indicated that the incidence of viral etiology ranges between 37.8% and 77.4% among patients with acute myocarditis in Europe.4,14 Although the true prevalence of COVID-19-related myocarditis is unknown, acute myocardial injury/damage appears to be common in patients with COVID-19.10,25 Clinical observations suggest that approximately one-quarter of hospitalized patients with COVID-19 have acute myocardial injury/damage with elevated cardiac tropon in levels14 to 20% and as much as 7% of deaths are attributable to COVID-19-related myocarditis.12,30 A meta-analysis, including 26 studies and 11685 patients with COVID-19 infection reported a weighted pooled prevalence of acute myocardial injury of 20%.11 The prevalence ranged from 5% to 38%, depending on the diagnostic criteria used in the studies. Recently, Belot and coworkers have reported that the rate of myocarditis is as high as 70% in COVID-19 cases with pediatric inflammatory multisystem syndrome.12

Early case reports on COVID-19-related myocarditis were sporadic. Ruan and colleagues first reported that myocarditis may be caused by SARS-CoV-2 infection.23 With the development of the COVID-19 pandemic, reports of COVID-19-related myocarditis cases have increased.10,25,53 In a retrospective multicenter study conducted to investigate the causes of death in patients with COVID-19 by using the database of the Jin Yin-tan Hospital and Tongji Hospital in China,25 among 68 deaths due to COVID-19 infection, 7% (five patients) died of myocarditis with circulatory failure, and 33% (22 patients) died of myocarditis and respiratory failure.25 These results indicate that myocarditis may contribute to the death of patients with COVID-19.12

The first direct evidence of COVID-19-related myocarditis by endomyocardial biopsy (EMB, regarded as the gold standard for the diagnosis of myocarditis) was reported in a 43-year-old woman with COVID-19.27 Diffuse T-lymphocytic inflammatory infiltrates with apparent interstitial edema and limited focal necrosis were documented, and no replacement fibrosis was detected with EMB. However, the SARS-CoV-2 genome was not detected within the myocardium. COVID-19-related fulminant myocarditis has even been diagnosed in a 2-year-old infant.24 Autopsy studies have revealed the detection of SARS-CoV-2 mRNA in the myocardium in five out of 12 COVID-19 victims.38

Beyond acute and life-threatening myocarditis in active COVID-19 infection, myocardial inflammation may also evolve as a delayed sequela of healed COVID-19.6,55,56,59,60 For example, Wenzel and colleagues have detected the expression of SARS-CoV-2-specific nucleic acid by EMB in two patients who were negative for COVID-19 according to nasopharyngeal swab testing; the authors found a positive result for the SARS-CoV-2 genome.60 A 31-year-old male diagnosed with myocarditis after COVID-19 recovery and discharged after 3 weeks has been speculated to have residual myocardial inflammation as a result of COVID-19.55

3. The mechanism underlying COVID-19-related myocarditis

The mechanism underlying COVID-19-related myocarditis is not well understood. The most plausible mechanisms are the down-regulation of angiotensin-converting enzyme (ACE2) expression and a hyper-inflammatory cytokine storm, which lead to myocarditis.31,46 ACE2 is highly expressed and attached to the cell membranes in the lung, heart, intestine, blood vessels, and other tissues; it is the host cell receptor for SARS-CoV-2, binding to the SARSCoV-2 spike entry.12,18,51 Compared with those of other SARS-CoVs, the structure of the SARS-CoV-2 binding site is more compact, with greater binding stability and significantly enhanced binding affinity to the ACE2 receptor.11,61

ACE2 has demonstrated immunoreactivity in cardiac myocytes.62–65 SARS-CoV-2 infection considerably downregulates ACE2 expression and impairs ACE2 function.56–58 The disruption of ACE2 impedes the effects of the protective signaling pathways in cardiac myocytes by increasing the release of pro-inflammatory cytokines, including tumor necrosis factor (TNF-α) and interleukin (IL)-6.56–68

Another probable mechanism is that SARS-CoV-2 infection may trigger a local immune response, recruit monocytes and T-cells, and release cytokines and chemokines, thus resulting in an inflammatory cytokine storm.57 Macrophage and T-lymphocytic cells have been confirmed to play a critical role in COVID-19-related myocarditis.57,156 In a 69-year-old patient from Italy with COVID-19-related myocarditis, large, vacuolated, and CD68+ macrophages with membrane damage and cytoplasmic vacuoles have been observed to infiltrate into the myocardium, on the basis of EMB with immunological light microscopy.59 Meanwhile, SARS-CoV-2 particles were detected in cardiac macrophages but not cardiomyocytes.55 A 43-year-old patient diagnosed with COVID-19-related myocarditis has been documented to have diffuse inflammatory infiltrates with myocardial edema, despite SARS-CoV-2 negativity, by using EMB.57 These data indicate that macrophages and T-lymphocytic cells play critical roles in COVID-19-related myocarditis.

Pathological monocytes and T-cells mediate the hyper-inflammatory cytokine storm in viral infection.51 SARS-CoV-2 infection induces the cytokine storm, mediated through monocytes and T-cells, thus leading to myocarditis.51 The cytokine storm caused by SARS-CoV-2 infection indicates an immune system gone awry and manifests as excessive increased plasma concentrations of proinflammatory cytokines such as IL-1β, IL-2, IL-6, IL-10, granulocyte colony-stimulating factor, interferon-γ-inducible protein 10, macrophage inflammatory protein 1 alpha, monocyte chemoattractant protein 1, and TNF-α.27 The pro-inflammatory cytokines spread throughout the body, including the heart, through the systemic circulation, even as the cytokine storm occurs in local organs or tissues.2 Thus, dysregulated immune and inflammatory function is important in COVID-19-related myocarditis.51

4. The role of the cholinergic anti-inflammatory pathway (CAP) in COVID-19-related myocarditis

In the past few decades, understanding the critical role of the neuroimmune system has been enhanced by the clarification of the overlapping distributions and interaction between the nervous system and immune system in the regulation of immunological and inflammatory responses.45,56,60 Among the neuroimmune interactions, the vagus nerve generated considerable interest when it was characterized as a major regulator of inflammation.21,32,70 Borovikova and colleagues have demonstrated that acetylcholine (ACh), the principle vagal neurotransmitter, significantly attenuates inflammation in the human macrophage response to lipopolysaccharide (LPS).23 An interesting and important finding is that the level of circulating TNF-α is significantly increased by bilateral cervical vagotomy in rats that were administered LPS but is markedly decreased when the distal end of the efferent vagus nerve is stimulated by constant voltage pulses in vagotomized rats that were administered LPS.20 Therefore, the vagus nerve pathway, termed the CAP, plays a major role in the neural control of inflammation and the neuroimmune dialogue.59,11

We hypothesized that the CAP, coinciding with the mechanism underlying COVID-19-related myocarditis, may play a crucial role in inhibiting inflammation in COVID-19-related myocarditis directly and/or through ACE-2. The principle vagal neurotransmitter ACh should bind ACh receptors, particularly γ7 nicotinic ACh receptors.
\(\alpha 7\text{nAChR}\), and consequently control immune cells and inhibit the production of inflammatory cytokines.\(^{96,71}\) The \(\alpha 7\text{nAChR}\) is composed of five identical \(\alpha 7\) subunits and is the central component of the CAP that influences anti-inflammatory cells. It is encoded by \(\text{AHRN}\alpha 7\) on chromosome 15q14 and is widely expressed on the surfaces of inflammatory cells, including macrophages, monocytes, T cells, B cells, and dendritic cells.\(^{72–75}\)

Wang and colleagues have found that the levels of NF-\(\alpha\)- \(\alpha 7\text{nAChR}\) mice were significantly attenuated in wild-type mice.\(^{42}\) When electrical stimulation is applied to the vagus nerve, endotoxin-induced serum TNF levels are significantly higher in endotoxemic \(\alpha 7\text{nAChR}\) than wild-type mice.\(^{42}\) Experiments in human macrophages and mouse peritoneal macrophages have further demonstrated that the release of TNF-\(\alpha\) by LPS from macrophages is inhibited by Ach and nicotine through the stimulation of \(\alpha 7\text{nAChR}\).\(^{72}\) In monocytes, \(\alpha 7\text{nAChR}\) activated by non- or strong agonists downregulates NF-\(\alpha\) significantly.\(^{72}\) De-Pu and colleagues have used nicotine to activate \(\alpha 7\text{nAChR}\) in mice with acute virus-induced myocarditis. The proportion of Th1 and Treg cells increases and that of Th1 and Th17 cells decreases in the spleen, thus indicating that the \(\alpha 7\) subunit is essential for the cholinergic suppression of TNF-\(\alpha\) and the normal regulation of systemic inflammatory responses.\(^{96,72}\)

Recently, several studies have demonstrated that \(\alpha 7\text{nAChR}\) is an important mediator of nicotine's upregulation of ACE-2.\(^{77,78}\) The main receptor used by SARS-CoV-2 to enter host cells is ACE-2.\(^{77,78}\) The repurposing of \(\alpha 7\text{nAChR}\) antagonists has been proposed as a method to alter ACE-2 expression and prevent SARS-CoV-2 entry,\(^{77,78}\) although the interaction between SARS-CoV-2 and ACE-2 requires further investigation.\(^{79}\) Beyond providing an entry point for SARS-CoV-2 into cardiac myocytes and suppressing inflammatory cytokines, ACE-2 interaction with SARS-CoV-2 facilitates detrimental effects on the parasympathetic tone and cardiovascular regulation.\(^{66}\) Therefore, targeting the CAP, particularly \(\alpha 7\text{nAChR}\), through vagus nerve stimulation (VNS) might be a useful therapeutic measure for patients with COVID-19-related myocarditis.\(^{80}\)

5. CAP as a prospective therapy for COVID-19-related myocarditis

Extending the seminal finding that the CAP inhibits acute inflammation, researchers have assessed the therapeutic potential of VNS and have reported promising therapeutic results for many diseases, including sepsis,\(^{75,80,87}\) dementia,\(^{58–61}\) arthritis,\(^{25,30}\) and cerebro- and cardiovascular diseases.\(^{81,82}\) Koopman has found that the serum levels of TNF-\(\alpha\), IL-1\(\beta\), and IL-6 significantly decrease, and the clinical symptoms improve, in patients with rheumatoid arthritis after 3 months of treatment with an implantable VNS device.\(^{83}\) In patients undergoing off-pump surgical revascularization, the peripheral blood production of TNF-\(\alpha\) and IL-6 significantly decreases after 6 h of VNS treatment.\(^{84}\) Additionally, some clinical trials that aim to assess the effects of VNS in diseases such as heart failure, atrial fibrillation, and traumatic brain injury are currently in progress.\(^{85}\)

Because of its safety and the absence of significant adverse effects, VNS has also been proposed as a potential therapeutic strategy for the current outbreak of COVID-19.\(^{40,80,85}\) Staats and coworkers\(^{44}\) have reported that patients with COVID-19 showed expedited symptomatic recovery from severe cough, chest tightness, and shortness of breath after noninvasive VNS. Leung\(^{78}\) and Russo\(^{77}\) have suggested that methyllycaconitine or \(\alpha 7\text{nAChR}\), repurposed \(\alpha 7\text{nAChR}\) antagonists, are potential medications for COVID-19, although this usage should be approached with caution.\(^{79}\)

Importantly, the CAP has been shown to decrease the inflammatory response in viral myocarditis.\(^{70,86}\) Activated \(\alpha 7\text{nAChR}\) by nicotine improves the balance of Th1/Th2 and Th17/Treg cell functional axis\(^{86}\) and significantly downregulates the expression of TNF-\(\alpha\) and IL-6 in mice with CVB3-induced viral myocarditis.\(^{50}\) In addition, \(\alpha 7\text{nAChR}\) plays an important role in the expression of ACE-2, the target receptor of SARS-CoV-2.\(^{96,72,78}\) Thus, CAP might be a promising and effective therapeutic avenue for treating COVID-19-related myocarditis.

6. Conclusions and expectations

In summary, the CAP plays an important role in COVID-19-related myocarditis. Targeted activation of the CAP might provide a potential and effective therapeutic method for SARS-CoV-2-induced myocarditis in the COVID-19 pandemic. However, the interaction between the CAP and SARS-CoV-2 infection, including COVID-19-related myocarditis, must be further investigated. Moreover, large sample, multicenter, and multiethnic prospective clinical trials are needed to further extensively assess the anti-inflammatory effects of the CAP in COVID-19-related myocarditis.

Funding

This work was supported by the National Natural Science Foundation of China (grant Nos. 81870281 and 81670432), the Zhejiang Provincial Natural Science Foundation of China (grant Nos. LY18H020011 and LQ19H020005), and the Academic Promotion Program of Shandong First Medical University.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Competing interests

The authors have no financial conflicts of interest.

References

[1]. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, HuangCL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, WangX, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, XiaoGF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
[2]. Babapoor-Farrokhran S, Gill D, Walker J, Raskeeper TI, Rozbortnia B, Amanullah A. Myocardial injury and COVID-19: Possible mechanisms. Life Sci. 2020;253:117723.
[3]. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. J Am Med Assoc. 2020;323(11):1239–1246.
[4]. Shi Y, Wang G, Cai XP, et al. An overview of COVID-19. J Zhejiang Univ - Sci B. 2020;21(5):343–360.
[5]. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autimmune. 2020;105:102433.
[6]. Guzik Tj, Mohiddin SA, Dimaro A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–1687.
[7]. Ranard LS, Fried JA, Abdalla M, et al. Approach to acute cardiovascular complications in COVID-19 infection. Circ Heart Fail. 2020;13(7):e007220.
[8]. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129–133.
[9]. Chan JW, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003;58(8):680–689.
Mechanisms of myocardial injury in patients hospitalized with COVID-19 infection: A review. JAMA Cardiol 2020;7(5):591–599.

[52] Belot A, Antona D, Renolleau S, et al. SARS-CoV-2-related paediatric myocarditis: A case report and review of the literature. Case Rep Cardiol 2020;2020:801061.

[54] Lippi G, Cetica V, Tufanelli F, et al. COVID-19: A cause of raised troponin and ECG changes. Clin Chem Lab Med 2020;58(6):1102–1103.

[56] Sardari A, Tabarsi P, Borhany H, Mohiaddin R, Housham G. Myocarditis among COVID-19 patients: A systemic review of cases. J Card Fail 2020;26(8):551–558.

[57] Sala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a fulminant myocarditis. Heart 2021;107(9):682–687.

[58] Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy findings in patients with COVID-19: A case series of 30 autopsies. Nat Med 2020;26(11):1663–1669.

[59] Wang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020;585(7821):221–224.

[60] Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and cardiovascular disease. J Mol Cell Cardiol 2020;147:304–316.

[61] Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and cardiovascular disease. J Mol Cell Cardiol 2020;147:304–316.

[62] Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and cardiovascular disease. J Mol Cell Cardiol 2020;147:304–316.

[63] Williamson D, Sperhacke JP, Gottschling EM, et al. Autoantibody findings and venous thromboembolism in patients with COVID-19. Ann Intern Med 2020;173(4):268–277.

[64] Wang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020;585(7821):221–224.

[65] Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and cardiovascular disease. J Mol Cell Cardiol 2020;147:304–316.

[66] Wang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020;585(7821):221–224.

[67] Wang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020;585(7821):221–224.

[68] Wang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020;585(7821):221–224.

[69] Wang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020;585(7821):221–224.

[70] Wang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020;585(7821):221–224.

[71] Wang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020;585(7821):221–224.
[70]. Berthoud HR, Neuhuber WL. Functional and chemical anatomy of the afferent vagal system. Auton Neurosci. 2000;85(1-3):1–17.

[71]. Ulloa L. The vagus nerve and the nicotinic anti-inflammatory pathway. Nat Rev Drug Discov. 2005;4(8):673–684.

[72]. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421(6921):384–388.

[73]. Lin ZH, Li YC, Wu SJ, et al. Eliciting α7-nAChR exerts cardioprotective effects on ischemic cardiomyopathy via activation of AMPK signalling. J Cell Mol Med. 2019;23(7):4746–4758.

[74]. Wu SJ, Li YC, Shi ZW, et al. Alteration of cholinergic anti-inflammatory pathway in rat with ischemic cardiomyopathy-modified electrophysiological function of heart. J Am Heart Assoc. 2017;6(9), e006510.

[75]. Farrish WR, Rosas-Ballina M, Gallowitsch-Puerta M, et al. Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling. Mol Med. 2008;14(9-10):567–574.

[76]. De-Pu Z, Li-Sha G, Guang-Yi C, et al. The cholinergic anti-inflammatory pathway ameliorates acute viral myocarditis in mice by regulating CD4⁺ T cell differentiation. Virulence. 2018;9(1):1364–1376.

[77]. Russo P, Bonassi S, Giacconi R, Malavolta M, Tomino C, Maggi F. COVID-19 and smoking: is nicotine the hidden link? Eur Respir J. 2020;56(1):2001116.

[78]. Leung JM, Yang CX, Sin DD. COVID-19 and nicotine as a mediator of ACE-2. Eur Respir J. 2020;55(6):2001261.

[79]. Farsalinos K, Angelopoulou A, Alexandris N, Poulas K. COVID-19 and the nicotinic cholinergic system. Eur Respir J. 2020;56(1):2001589.

[80]. Bonaz B, Sinniger V, Pellissier S. Targeting the cholinergic anti-inflammatory pathway with vagus nerve stimulation in patients with Covid-19? Bioelectrochem Med. 2020;6:15.

[81]. Duris K, Lipkova J, Jurajda M. Cholinergic anti-inflammatory pathway and stroke. Curr Drug Deliv. 2017;14(4):449–457.

[82]. Hilderman M, Qureshi AR, Abrahi F, et al. The cholinergic anti-inflammatory pathway in resistant hypertension treated with renal denervation. Mol Med. 2019;25(1):39.

[83]. Koopman FA, Chavan SS, Miljko S, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2016;113(29):9439–950.

[84]. Rossi P, Ricci A, De Paulis R, et al. Epicardial ganglionic plexus stimulation decreases postoperative inflammatory response in humans. Heart Rhythm. 2012;9(6):943–950.

[85]. Andersson Ulf. The cholinergic anti-inflammatory pathway alleviates acute lung injury. Mol Med. 2020;26(1):64.

[86]. Cheng Z, Li-Sha G, Jing-Lin Z, et al. Protective role of the cholinergic anti-inflammatory pathway in a mouse model of viral myocarditis. PloS One. 2014;9(11), e112719.